The influx of capital brings together a coalition of major healthcare stakeholders, including Humana and CVS Health Ventures, alongside institutional backers such as a16z Bio + Health and Frist Cressey Ventures. Currently, Thyme Care manages over $7 billion in oncology spending and provides services to more than 10.5 million individuals. By integrating care teams directly into clinical workflows, the company claims to achieve a 5 to 10 percent reduction in total care costs while maintaining profitability.

The creation of Thyme Companies marks a strategic evolution for the organization. Co-founder Robin Shah will transition to executive chairman of the new parent entity, focusing on launching independent businesses that target persistent systemic hurdles. Initial projects include accelerating the adoption of cost-effective biosimilars and streamlining clinical trial enrollment, with the first of these new ventures expected to launch by the end of 2026.

Leadership at the core business remains stable as the organization scales. Dr. Brad Diephuis continues as CEO of Thyme Care, working alongside co-founder and Chief Medical Officer Dr. Bobby Green. The company maintains that while the new parent structure allows for broader innovation, Thyme Care will remain the anchor of the portfolio, preserving its existing partnerships and patient care model.